AU2002242214A1 - Inhibition of atf2 activity to treat cancer - Google Patents

Inhibition of atf2 activity to treat cancer

Info

Publication number
AU2002242214A1
AU2002242214A1 AU2002242214A AU2002242214A AU2002242214A1 AU 2002242214 A1 AU2002242214 A1 AU 2002242214A1 AU 2002242214 A AU2002242214 A AU 2002242214A AU 2002242214 A AU2002242214 A AU 2002242214A AU 2002242214 A1 AU2002242214 A1 AU 2002242214A1
Authority
AU
Australia
Prior art keywords
atf2
therapies
inhibition
treat cancer
provides methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002242214A
Inventor
Ronai Ze'ev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of AU2002242214A1 publication Critical patent/AU2002242214A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention relates to novel therapies for cancer and, in particular, to therapies that are particularly suited to tumor cells resistant to other types of therapies such as radiation, chemotherapy, or combinations of both approaches. The invention provides methods for identifying and implementing strategies to inhibit a transcription factor which, in combination with other factors, renders the cells resistant and inhibits apopotosis of the cells. The invention provides an inhibitory ATF2 N-terminal fragment, specifically a fragment corresponding to amino acid residues 50-100 of ATF2 (termed peptide II). The invention provides methods for inhibiting tumor cell growth with such peptides.
AU2002242214A 2001-02-15 2002-02-14 Inhibition of atf2 activity to treat cancer Abandoned AU2002242214A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26911801P 2001-02-15 2001-02-15
US60/269,118 2001-02-15
US26925701P 2001-02-16 2001-02-16
US60/269,257 2001-02-16
PCT/US2002/005215 WO2002064025A2 (en) 2001-02-15 2002-02-14 Inhibition of atf2 activity to treat cancer

Publications (1)

Publication Number Publication Date
AU2002242214A1 true AU2002242214A1 (en) 2002-08-28

Family

ID=26953513

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002242214A Abandoned AU2002242214A1 (en) 2001-02-15 2002-02-14 Inhibition of atf2 activity to treat cancer

Country Status (6)

Country Link
US (2) US7314855B2 (en)
EP (1) EP1368049B1 (en)
AT (1) ATE405283T1 (en)
AU (1) AU2002242214A1 (en)
DE (1) DE60228419D1 (en)
WO (1) WO2002064025A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064785A2 (en) * 2003-01-14 2004-08-05 Dana Farber Cancer Institute Cancer therapy sensitizer
WO2006044984A1 (en) * 2004-10-18 2006-04-27 Mount Sinai School Of Medicine Of New York University Inhibition of tumor growth and metastasis by atf2-derived peptides
EP1827471B1 (en) * 2004-11-09 2011-01-12 Celtek Bioscience, Llc. Composition and method for increasing apoptosis in cancer cells
WO2009026163A1 (en) * 2007-08-17 2009-02-26 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
US20130225503A1 (en) * 2009-09-30 2013-08-29 Baylor Licnensing Group Tex14 peptides as novel antitumor agents
US9029340B2 (en) 2010-07-22 2015-05-12 The Johns Hopkins University Radiation sensitization agents for prostate cancer
US20120095078A1 (en) * 2010-10-07 2012-04-19 Sanford-Burnham Medical Research Institute Methods of diagnosis and treatment of melanoma
CN106420712B (en) * 2015-08-10 2020-09-25 上海市中医老年医学研究所 Application of anisomycin in preparing medicine for preventing/treating ovarian cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736381A (en) 1995-05-19 1998-04-07 Davis; Roger J. Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
EP1023313A1 (en) * 1997-05-28 2000-08-02 Daniel A. Mercola Inhibition of stress activated protein kinase (sapk) pathway and sensitization of cells to cancer therapies
US6022952A (en) * 1998-04-01 2000-02-08 University Of Alberta Compositions and methods for protein secretion

Also Published As

Publication number Publication date
EP1368049A2 (en) 2003-12-10
US7935525B2 (en) 2011-05-03
DE60228419D1 (en) 2008-10-02
EP1368049B1 (en) 2008-08-20
WO2002064025A3 (en) 2002-12-19
US20080139475A1 (en) 2008-06-12
US20020169121A1 (en) 2002-11-14
WO2002064025A2 (en) 2002-08-22
US7314855B2 (en) 2008-01-01
EP1368049A4 (en) 2004-09-08
ATE405283T1 (en) 2008-09-15

Similar Documents

Publication Publication Date Title
WO2003089457B1 (en) Peptide inhibitors of protein kinase c ϝ for pain management
WO2006116381A3 (en) Plasma or serum fraction for treatment or prevention of abnormal cell proliferation
WO2005077091A8 (en) Nicotinamide riboside kinase compositions and methods for using the same
WO2006116322A3 (en) Nicotinamide riboside kinase compositions and methods for using the same
ATE332386T1 (en) DEFECTIVE RECOMBINANT ADENOVIRUSES FOR TUMOR GENE THERAPY
AU2002242214A1 (en) Inhibition of atf2 activity to treat cancer
Weber et al. Posttranslational modifications of α-and β-tubulin in Giardia lamblia, an ancient eukaryote
Resing et al. Characterization of protease processing sites during conversion of rat profilaggrin to filaggrin
WO2005123760A3 (en) Treating cancer
Munawar et al. Venom peptide analysis of Vipera ammodytes meridionalis (Viperinae) and Bothrops jararacussu (Crotalinae) demonstrates subfamily-specificity of the peptidome in the family Viperidae
WO2001009189A3 (en) Compositions and methods for the treatment of tumors
GB2358864B (en) Peptides
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
EP2343311A3 (en) Peptide inhibitors of HK2 and their use
ATE362768T1 (en) PRB2/P130 PEPTIDE INHIBITORS OF CDK2 KINASE ACTIVITY
IL189502A0 (en) Methods and compositions for inhibiting neoplastic cell growth
Kariya et al. Inhibition of angiotensin converting enzyme of rat brain with bradykinin and its fragments
WO2003033024A1 (en) Cell proliferation inhibitor
WO2007129999A3 (en) Antiproliferative peptides and antibodies for their detection
SE9700301D0 (en) New compound
Hayakari et al. Kinetic-controlled hydrolysis of Leu-Val-Val-hemorphin-7 catalyzed by angiotensin-converting enzyme from rat brain
WO2021062389A3 (en) Peptide for treating cancer
WO2006067406B1 (en) Immunomodulatory peptide fragments of cd23 and uses therefor
WO2023143610A3 (en) C-TERMINAL FRAGMENT OF APOLIPOPROTEIN E AND APPLICATION THEREOF IN INHIBITING γ-SECRETASE ACTIVITY
AU2118500A (en) Transcription factor e2f dna-binding domain inhibitor peptides and their use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase